Posaconazole
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Aplastic Anemia
Conditions
Aplastic Anemia, Myelodysplastic Syndromes, Fungal Infection
Trial Timeline
Apr 20, 2018 → Jul 15, 2023
NCT ID
NCT03318159About Posaconazole
Posaconazole is a phase 2 stage product being developed by Merck for Aplastic Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03318159. Target conditions include Aplastic Anemia, Myelodysplastic Syndromes, Fungal Infection.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00686621 | Pre-clinical | Completed |
| NCT05065658 | Pre-clinical | Completed |
| NCT03318159 | Phase 2 | Completed |
| NCT03336502 | Phase 1 | Completed |
| NCT02387983 | Phase 1 | Completed |
| NCT02020213 | Approved | Withdrawn |
| NCT00811642 | Phase 3 | Completed |
| NCT00686543 | Approved | Completed |
| NCT00550732 | Phase 2 | Completed |
| NCT00726609 | Pre-clinical | Completed |
| NCT00034658 | Phase 3 | Completed |
Competing Products
20 competing products in Aplastic Anemia